May 12, 2021 7:48am

Not quite Abbott and Costello, the words alone cannot do it justice

Pre-open indications:  5 BUYs, 4 SELLs and 1 Maintain SELL

Mentions: AGTC, IONS, MESO, NTLA, BLUE, BSTG, CLLS, GBT, VYGR, RENE.L

My version of the morning’s “indications” is written to be informative; it’s what could happen or materialize after the opening and what might happen during the session

Subscription is coming, it’s not conscription but, an offer to join our collective of like-minded investors!  


Dow futures are DOWN -0.35% (-120 points), S&P futures are DOWN -0.40% (-17 points) and NASDAQ futures are DOWN -0.63% (-84 points)

 

U.S. stock futures declined in early trading Wednesday

European markets cautiously higher;

Asia-Pacific shares were mostly down

 

Data Docket: Key inflation data will be released at 8:30 a.m. ET. (Many traders and investors have grown worried that a rapid rise in inflation may force central banks to raise interest rates and implement other tightening measures)

 

Henry’omics:

On Tuesday, cell and gene therapy sector stocks fell but eventually recovered but, will it spur further selling in this market?

The “fear gauge” or the CBOE Volatility Index jumped as high as 23.73, leveling-off at 21.84, it hasn’t been as high for months.

 

Q1/21 Earnings: <posted>: twenty-three (23) to date …  https://www.regmedinvestors.com/articles/11628

 

Tuesday’s evening’s recap: “the oversold got recognized as dips got bought. The problem is, they will be considered overbought in next few sessions as the sector had briefly fallen out of favor earlier this month with earnings’ notching its belt.” … https://www.regmedinvestors.com/articles/11906

  • The Nasdaq closed DOWN -12.43 points (-0.09%);
  • The IBB closed up +0.55% and XBI closed up +1.63%
  • Sector volume was LOW with 7 of the 23-upside having higher than the 3-month average volume with the volume of 5 of 10-downside having higher than the 3-month average volume;
  • The CBOE Volatility Index (VVIX: INDEX) was up +2.18 point or +11.09% at 21.84;
  • Tuesday’s percentage (%) of the 23-upside were +0.22% (SLDB) to +8.42% (NTLA) while the 10-downside ranges from -0.61% (RGNX) to -9.52% (RENE.L);

Q2/21:

May:  2 positive and 5 negative closes

April: 11 negative and 10 positive closes

Q1/21:

  • March: 10 positive, 12 negative and 1 neutral closes
  • February: 9 positive, 10 negative closes and 1 holiday
  • January: 10 positive, 9 negative closes and 1 holiday

 

Companies in my headlights – It’s your decision; I provide an idea and context:

Biostage (BSTG): Questions continue … Maintaining Sell

Biostage (BSTG) closed flat at $1.20 with 388 shares traded after Monday’s +$0.05 to $1.20 with 1,888 shares traded, Friday’s +$0.02 to $1.15 with 2,364 shares traded (the “pump and promote” was back), Thursday’s +0.02 to $1.13 with 207 shares traded and last Wednesday’s -$0.01 to $1.11 with 3,032 shares traded.

Question#1: Measure the volume and the pricing movement; WHY hasn’t the constancy of “promoting and pumping” the share price come to the attention of regulatory officials?

Question#2: With only $1 million left in the “till” WHAT is the runway with a “spend” and “net cash in operations of $4 million during the year ended 12/ 31/20”. Don’t forget the PPP loan remaining as DEBT ($0.4 million).

MINORITY PUBLIC shareholders are waiting, watching and weighing responses to MAINTAIN their RIGHTS.

 

The morning’s indications, from what I discern are in store:

Maintaining SELL:

  • bluebird bio (BLUE) closed up +$1.10 to $29.50 after Monday’s -$2.08 to $28.40 and has a negative -$0.50 or -1.69% aftermarket indication.
  • Cellectis SA (CLLS) closed up +$0.88 to $15.88 after Monday’s -$1.30 to $15.00, Friday’s +$0.77 to $16.30 and Thursday’s -$1.41 with a negative -$0.03 or -0.19% aftermarket indication.
  • Global Blood Therapeutics (GBT) closed up +$0.32 to $37.79 after Monday’s $37.47, Friday’s $38.62, Thursday’s $38.23 and last Wednesday’s $39.83 with a negative -$0.09 or -0.24% aftermarket indication.
  • Voyager Therapeutics (VYGR) closed up +$0.29 to $4.40 after Monday’s $4.11, Friday’s $4.31, Thursday’s $4.38 and last Wednesday’s $4.28 with a negative -$0.13 or -2.95% aftermarket indication.

BUY:

  • Applied Genetic Technology (AGTC) closed down -$0.13 to $3.68 after Monday’s -$0.08 to $3.81 with a positive +$0.08 or +2.17% aftermarket indication.
  • Ionis Pharmaceuticals (IONS) closed up +$0.45 to $36.69 after Monday’s $36.24 and Friday’s $36.54 with a positive +$0.76 or +2.07% aftermarket indication.
  • Mesoblast (MESO) closed down -$0.35 to $6.75 after Monday’s $7.10 and Friday’s $6.98 with a positive +$0.24 or +3.50% aftermarket indication.
  • Intellia Therapeutics (NTLA) closed up +$5.14 to $66.17 after Monday’s -$6.71 to $61.03 with a positive +$0.83 or +1.25% aftermarket indication.
  • ReNeuron (RENE.L) closed down again -$14.00 after Monday’s -$0.50 after Friday’s -$1.00 after Thursday’s +$1.00 after Wednesday’s +$2.00 after Tuesday’s +$7.00 and has a positive indication of +$0.40 or +0.30% pre-market indication.

 

The BOTTOM LINE: Investor expectations have NOT been high during “our’ sector earnings season.  I haven’t been wrong in seeing trouble ahead in the markets and any prognostication could be somewhat difficult or unpleasant.

My focus has always been “warning analysis” … my advice, trim and skim any new highs if one can!” I also see some lows that could be in the “pick-up” stock game.

My motto, never leave an investor uninformed about what I know!

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.